FDA
-
-
-
-
-
-
-
MBX Biosciences names new CEO and CFO amid leadership shift
-
-
-
-
-
-
-
MBX Biosciences names Mark Soued as chief commercial officer
-
-
-
-
-
-
-
MBX Biosciences completes FDA meeting for phase 3 hypoparathyroidism trial
-
-
-
-
-
-
-
Microbix Reports Results for Q4 and Fiscal 2025
-
-
-
-
-
-
-
MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Microbix Client Labquality Introduces Novel EQA Scheme at ESCV
-
-
-
-
-
-
-
Microbix Launches QUANTDx™ Characterized Reference Materials
-
334,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


